ALNYLAM PHARMACEUTICALS, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ALNYLAM PHARMACEUTICALS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
47.2
89.9
74.9
220
493
844
1,037
1,828
2,248
3,714
Cost of revenue
0
1.8
25.1
74.2
115
140
268
307
677
Gross profit
89.9
73.1
195
419
729
897
1,560
1,942
3,037
Research and development
382
391
505
655
655
792
883
1,004
1,126
1,320
Selling, general and administrative
89.4
199
382
479
588
621
771
796
976
1,211
General and administrative
89.4
199
Operating expenses
472
590
Operating income
-425
-500
-815
-939
-828
-709
-785
-282
-177
502
Interest expense
0
0
84.5
143
156
121
142
253
Interest income
29.3
33.4
11.8
1.58
24.8
95.6
122
111
Other non-operating income
14.5
9.21
54
54.2
-27.2
-143
-342
-151
-200
-178
Pre-tax income
-410
-491
-761
-885
-856
-852
-1,127
-434
-377
323
Income tax
0
0
0.82
0.86
2.68
0.68
4.16
6.73
-99.2
9.41
Net income
-410
-491
-761
-886
-858
-853
-1,131
-440
-278
314
EBITDA
-409
-487
-799
-922
-794
-661
-741
-228
-120
557
EPS, basic
-4.79
-5.42
-7.57
-8.11
-7.46
-7.20
-9.30
-3.52
-2.18
2.39
EPS, diluted
-4.79
-5.42
-7.57
-8.11
-7.46
-7.20
-9.30
-3.52
-2.18
2.33
Shares, basic (weighted)
85.6
90.6
101
109
115
118
122
125
128
131
Shares, diluted (weighted)
85.6
90.6
101
109
115
118
122
125
128
135
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
194
645
420
547
497
820
866
813
966
1,657
Short-term investments
424
1,045
663
975
1,333
1,549
1,298
1,616
1,720
1,251
Receivables
23.3
34
18.8
43
102
199
238
328
405
778
Inventory
24.1
56.3
75.2
86.4
129
89.1
78.5
82.7
Other current assets
21.7
40.1
73.7
80.3
62.8
88.1
133
126
117
282
Total current assets
672
1,765
1,201
1,716
2,615
2,809
2,692
2,983
3,295
4,051
Property, plant and equipment
115
182
321
425
465
502
523
526
503
513
Lease right-of-use assets
221
241
232
215
200
191
195
Long-term investments
325
13.9
Other non-current assets
1.56
4.17
8.62
18.1
45
60.2
66.1
61.9
65.3
59.5
Total assets
1,263
1,995
1,575
2,395
3,407
3,643
3,546
3,830
4,240
4,966
Accounts payable
54.5
28.4
59.7
49.9
52
73.4
98.1
55.5
88.4
116
Accrued liabilities
42.1
72.2
113
197
356
395
545
713
794
1,080
Deferred revenue
33.5
41.7
3.5
77.8
127
149
42.1
103
55.5
4.85
Total current liabilities
132
144
179
353
585
696
768
968
1,186
1,466
Lease liabilities
276
293
281
261
243
230
225
Other non-current liabilities
3.07
4.35
4.97
9.33
37.9
99
213
308
4.97
7.59
Total liabilities
343
228
273
956
2,391
3,055
3,705
4,051
4,173
4,177
Total debt
191
676
Paid-in capital
2,610
3,948
4,175
5,201
5,644
6,058
6,455
6,811
7,388
7,510
Retained earnings
-1,657
-2,148
-2,841
-3,727
-4,585
-5,438
-6,569
-7,010
-7,288
-6,703
Other comprehensive income
-33.4
-34.4
-33.2
-36.5
-43.6
-33.3
-44.7
-23.4
-34.5
-20.1
Shareholders' equity
920
1,766
1,302
1,439
1,016
588
-158
-221
67.1
789
Total equity
920
1,766
1,302
1,439
1,016
588
-158
-221
67.1
789
Total liabilities and equity
1,263
1,995
1,575
2,395
3,407
3,643
3,546
3,830
4,240
4,966
Shares outstanding
85.9
99.7
101
112
116
120
124
126
129
132
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-410
-491
-761
-886
-858
-853
-1,131
-440
-278
314
Depreciation and amortization
15.1
13.4
15.2
17.2
34.8
47.6
44.5
54.1
56.7
55.7
Stock-based compensation
75.5
92.8
158
175
140
166
231
222
272
348
Deferred income tax
0
-0.79
-1.98
-3.22
-2.77
-1.43
-0.71
-107
-2.2
Change in receivables
-15
-10.7
15.2
-24.2
-56.2
-102
-45.6
-87.9
-86.6
-360
Change in inventory
0
-22.6
-32.4
-35.4
-26.4
-34.1
18.4
13.6
8.47
Change in payables
10.1
-4.94
15.5
92.4
144
88.2
192
80.8
91.1
75.1
Cash from operations
-308
-383
-563
-278
-615
-642
-541
104
-8.31
524
Capital expenditures
-64.6
-104
-127
-140
-70.4
-76.4
-72.1
-62.2
-34.3
-58.7
Purchases of investments
-759
-903
-1,104
-2,076
-2,026
-1,656
-1,977
-1,824
-1,635
-1,305
Sales and maturities of investments
1,116
597
1,519
1,775
1,692
1,464
2,232
1,554
1,572
1,802
Cash from investing
143
-290
273
-418
-436
-273
169
-336
-117
436
Debt repaid
0
0
-762
Stock issued
1,140
0
382
0
0
Cash from financing
178
1,125
65.5
823
995
1,247
426
172
294
-305
Exchange rate effect
0
0
-0.08
4.92
-9.02
-7.43
6.39
-15.2
34.9
Net change in cash
12.7
452
-224
127
-50.6
323
46.4
-53.7
154
690
Free cash flow
-372
-487
-690
-419
-685
-718
-613
41.9
-42.6
465
Interest paid
1.1
2.43
0.78
0.17
0
24.7
45.2
32.1
67.6
219
Income taxes paid
0.11
0.11
1.07
2.57
2.65
6.02
14.4
15.1
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $255.96 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
57.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
13.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
65.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
53.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
49.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
56.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
50.1%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
48.6%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
1,076.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
-4.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
17.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
11.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
7.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
5.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
3.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
3.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.05x
Current assets / current liabilities.
Quick ratio
2.79x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.19x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Book value per share
$10.13
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
44.2x
Market cap / net income. Only when net income is positive.
P/B
25.3x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
25.3x
Market cap / tangible book value, when positive.
Earnings yield
2.3%
Net income / market cap (the inverse of P/E).
What was ALNYLAM PHARMACEUTICALS, INC.'s revenue in fiscal 2025?
ALNYLAM PHARMACEUTICALS, INC. reported revenue of $3.71B for fiscal 2025, 65.2% higher than the year before.
Was ALNYLAM PHARMACEUTICALS, INC. profitable in fiscal 2025?
Yes. Net income was $313.7M, a net margin of 8.4%.
How much free cash flow did ALNYLAM PHARMACEUTICALS, INC. generate in fiscal 2025?
Cash from operations of $524.1M minus capital expenditures of $58.7M left free cash flow of $465.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.